Global Anti-Viral Drugs Market Research Report 2022
Global Anti-Viral Drugs Market Overview:
Global Anti-Viral Drugs Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Anti-Viral Drugs involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Anti-Viral Drugs Market
The Anti-Viral Drugs Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Anti-Viral Drugs Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Anti-Viral Drugs Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Anti-Viral Drugs Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Anti-Viral Drugs market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Anti-Viral Drugs Market Segmentation
Global Anti-Viral Drugs Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Anti-Viral Drugs market has been segmented into:
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Application, Anti-Viral Drugs market has been segmented into:
Hospitals
Research Institutes
Laboratory Centers
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Anti-Viral Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Anti-Viral Drugs market.
Top Key Players Covered in Anti-Viral Drugs market are:
Gilead Sciences
Merck
Roche
Johnson & Johnson
Bristol-Myers Squibb
GlaxoSmithKline
Novartis
AbbVie
Objective to buy this Report:
1. Anti-Viral Drugs analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Anti-Viral Drugs market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Global Anti-Viral Drugs Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Anti-Viral Drugs involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Anti-Viral Drugs Market
The Anti-Viral Drugs Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Anti-Viral Drugs Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Anti-Viral Drugs Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Anti-Viral Drugs Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Anti-Viral Drugs market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Anti-Viral Drugs Market Segmentation
Global Anti-Viral Drugs Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Anti-Viral Drugs market has been segmented into:
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Application, Anti-Viral Drugs market has been segmented into:
Hospitals
Research Institutes
Laboratory Centers
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Anti-Viral Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Anti-Viral Drugs market.
Top Key Players Covered in Anti-Viral Drugs market are:
Gilead Sciences
Merck
Roche
Johnson & Johnson
Bristol-Myers Squibb
GlaxoSmithKline
Novartis
AbbVie
Objective to buy this Report:
1. Anti-Viral Drugs analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Anti-Viral Drugs market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
CHAPTER 1: INTRODUCTION
1.1 RESEARCH OBJECTIVES
1.2 RESEARCH METHODOLOGY
1.3 RESEARCH PROCESS
1.4 SCOPE AND COVERAGE
1.4.1 MARKET DEFINITION
1.4.2 KEY QUESTIONS ANSWERED
1.5 MARKET SEGMENTATION
CHAPTER 2:EXECUTIVE SUMMARY
CHAPTER 3:GROWTH OPPORTUNITIES BY SEGMENT
3.1 BY TYPE
3.2 BY APPLICATION
CHAPTER 4: MARKET LANDSCAPE
4.1 PORTER'S FIVE FORCES ANALYSIS
4.1.1 BARGAINING POWER OF SUPPLIER
4.1.2 THREAT OF NEW ENTRANTS
4.1.3 THREAT OF SUBSTITUTES
4.1.4 COMPETITIVE RIVALRY
4.1.5 BARGAINING POWER AMONG BUYERS
4.2 INDUSTRY VALUE CHAIN ANALYSIS
4.3 MARKET DYNAMICS
4.3.1 DRIVERS
4.3.2 RESTRAINTS
4.3.3 OPPORTUNITIES
4.5.4 CHALLENGES
4.4 PESTLE ANALYSIS
4.5 TECHNOLOGICAL ROADMAP
4.6 REGULATORY LANDSCAPE
4.7 SWOT ANALYSIS
4.8 PRICE TREND ANALYSIS
4.9 PATENT ANALYSIS
4.10 ANALYSIS OF THE IMPACT OF COVID-19
4.10.1 IMPACT ON THE OVERALL MARKET
4.10.2 IMPACT ON THE SUPPLY CHAIN
4.10.3 IMPACT ON THE KEY MANUFACTURERS
4.10.4 IMPACT ON THE PRICING
CHAPTER 5: ANTI-VIRAL DRUGS MARKET BY TYPE
5.1 ANTI-VIRAL DRUGS MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
5.2 ANTI-VIRAL DRUGS MARKET OVERVIEW
5.3 DNA POLYMERASE INHIBITORS
5.3.1 INTRODUCTION AND MARKET OVERVIEW
5.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.3.4 DNA POLYMERASE INHIBITORS: GEOGRAPHIC SEGMENTATION
5.4 REVERSE TRANSCRIPTASE INHIBITORS
5.4.1 INTRODUCTION AND MARKET OVERVIEW
5.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.4.4 REVERSE TRANSCRIPTASE INHIBITORS: GEOGRAPHIC SEGMENTATION
5.5 PROTEASE INHIBITORS
5.5.1 INTRODUCTION AND MARKET OVERVIEW
5.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.5.4 PROTEASE INHIBITORS: GEOGRAPHIC SEGMENTATION
5.6 NEURAMINIDASE INHIBITORS
5.6.1 INTRODUCTION AND MARKET OVERVIEW
5.6.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.6.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.6.4 NEURAMINIDASE INHIBITORS: GEOGRAPHIC SEGMENTATION
5.7 OTHERS
5.7.1 INTRODUCTION AND MARKET OVERVIEW
5.7.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.7.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.7.4 OTHERS: GEOGRAPHIC SEGMENTATION
CHAPTER 6: ANTI-VIRAL DRUGS MARKET BY APPLICATION
6.1 ANTI-VIRAL DRUGS MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
6.2 ANTI-VIRAL DRUGS MARKET OVERVIEW
6.3 HOSPITALS
6.3.1 INTRODUCTION AND MARKET OVERVIEW
6.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.3.4 HOSPITALS: GEOGRAPHIC SEGMENTATION
6.4 RESEARCH INSTITUTES
6.4.1 INTRODUCTION AND MARKET OVERVIEW
6.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.4.4 RESEARCH INSTITUTES: GEOGRAPHIC SEGMENTATION
6.5 LABORATORY CENTERS
6.5.1 INTRODUCTION AND MARKET OVERVIEW
6.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.5.4 LABORATORY CENTERS: GEOGRAPHIC SEGMENTATION
6.6 OTHERS
6.6.1 INTRODUCTION AND MARKET OVERVIEW
6.6.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.6.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.6.4 OTHERS: GEOGRAPHIC SEGMENTATION
CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS
7.1 COMPETITIVE LANDSCAPE
7.1.1 COMPETITIVE POSITIONING
7.1.2 ANTI-VIRAL DRUGS SALES AND MARKET SHARE BY PLAYERS
7.1.3 INDUSTRY BCG MATRIX
7.1.4 HEAT MAP ANALYSIS
7.1.5 ANTI-VIRAL DRUGS INDUSTRY CONCENTRATION RATIO (CR5 AND HHI)
7.1.6 TOP 5 ANTI-VIRAL DRUGS PLAYERS MARKET SHARE
7.1.7 MERGERS AND ACQUISITIONS
7.1.8 BUSINESS STRATEGIES BY TOP PLAYERS
7.2 GILEAD SCIENCES
7.2.1 COMPANY OVERVIEW
7.2.2 KEY EXECUTIVES
7.2.3 COMPANY SNAPSHOT
7.2.4 OPERATING BUSINESS SEGMENTS
7.2.5 PRODUCT PORTFOLIO
7.2.6 BUSINESS PERFORMANCE
7.2.7 KEY STRATEGIC MOVES AND RECENT DEVELOPMENTS
7.2.8 SWOT ANALYSIS
7.3 MERCK
7.4 ROCHE
7.5 JOHNSON & JOHNSON
7.6 BRISTOL-MYERS SQUIBB
7.7 GLAXOSMITHKLINE
7.8 NOVARTIS
7.9 ABBVIE
CHAPTER 8: GLOBAL ANTI-VIRAL DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
8.1 MARKET OVERVIEW
8.2 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
8.2.1 DNA POLYMERASE INHIBITORS
8.2.2 REVERSE TRANSCRIPTASE INHIBITORS
8.2.3 PROTEASE INHIBITORS
8.2.4 NEURAMINIDASE INHIBITORS
8.2.5 OTHERS
8.3 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
8.3.1 HOSPITALS
8.3.2 RESEARCH INSTITUTES
8.3.3 LABORATORY CENTERS
8.3.4 OTHERS
CHAPTER 9: NORTH AMERICA ANTI-VIRAL DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
9.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.2 IMPACT OF COVID-19
9.3 KEY PLAYERS
9.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
9.4.1 DNA POLYMERASE INHIBITORS
9.4.2 REVERSE TRANSCRIPTASE INHIBITORS
9.4.3 PROTEASE INHIBITORS
9.4.4 NEURAMINIDASE INHIBITORS
9.4.5 OTHERS
9.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
9.5.1 HOSPITALS
9.5.2 RESEARCH INSTITUTES
9.5.3 LABORATORY CENTERS
9.5.4 OTHERS
9.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
9.6.1 U.S.
9.6.2 CANADA
9.6.3 MEXICO
CHAPTER 10: EUROPE ANTI-VIRAL DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
10.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.2 IMPACT OF COVID-19
10.3 KEY PLAYERS
10.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
10.4.1 DNA POLYMERASE INHIBITORS
10.4.2 REVERSE TRANSCRIPTASE INHIBITORS
10.4.3 PROTEASE INHIBITORS
10.4.4 NEURAMINIDASE INHIBITORS
10.4.5 OTHERS
10.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
10.5.1 HOSPITALS
10.5.2 RESEARCH INSTITUTES
10.5.3 LABORATORY CENTERS
10.5.4 OTHERS
10.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
10.6.1 GERMANY
10.6.2 U.K.
10.6.3 FRANCE
10.6.4 ITALY
10.6.5 RUSSIA
10.6.6 SPAIN
10.6.7 REST OF EUROPE
CHAPTER 11: ASIA-PACIFIC ANTI-VIRAL DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
11.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.2 IMPACT OF COVID-19
11.3 KEY PLAYERS
11.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
11.4.1 DNA POLYMERASE INHIBITORS
11.4.2 REVERSE TRANSCRIPTASE INHIBITORS
11.4.3 PROTEASE INHIBITORS
11.4.4 NEURAMINIDASE INHIBITORS
11.4.5 OTHERS
11.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
11.5.1 HOSPITALS
11.5.2 RESEARCH INSTITUTES
11.5.3 LABORATORY CENTERS
11.5.4 OTHERS
11.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
11.6.1 CHINA
11.6.2 INDIA
11.6.3 JAPAN
11.6.4 SINGAPORE
11.6.5 AUSTRALIA
11.6.6 NEW ZEALAND
11.6.7 REST OF APAC
CHAPTER 12: MIDDLE EAST & AFRICA ANTI-VIRAL DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
12.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.2 IMPACT OF COVID-19
12.3 KEY PLAYERS
12.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
12.4.1 DNA POLYMERASE INHIBITORS
12.4.2 REVERSE TRANSCRIPTASE INHIBITORS
12.4.3 PROTEASE INHIBITORS
12.4.4 NEURAMINIDASE INHIBITORS
12.4.5 OTHERS
12.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
12.5.1 HOSPITALS
12.5.2 RESEARCH INSTITUTES
12.5.3 LABORATORY CENTERS
12.5.4 OTHERS
12.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
12.6.1 TURKEY
12.6.2 SAUDI ARABIA
12.6.3 IRAN
12.6.4 UAE
12.6.5 AFRICA
12.6.6 REST OF MEA
CHAPTER 13: SOUTH AMERICA ANTI-VIRAL DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
13.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.2 IMPACT OF COVID-19
13.3 KEY PLAYERS
13.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
13.4.1 DNA POLYMERASE INHIBITORS
13.4.2 REVERSE TRANSCRIPTASE INHIBITORS
13.4.3 PROTEASE INHIBITORS
13.4.4 NEURAMINIDASE INHIBITORS
13.4.5 OTHERS
13.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
13.5.1 HOSPITALS
13.5.2 RESEARCH INSTITUTES
13.5.3 LABORATORY CENTERS
13.5.4 OTHERS
13.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
13.6.1 BRAZIL
13.6.2 ARGENTINA
13.6.3 REST OF SA
CHAPTER 14 INVESTMENT ANALYSIS
CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION
1.1 RESEARCH OBJECTIVES
1.2 RESEARCH METHODOLOGY
1.3 RESEARCH PROCESS
1.4 SCOPE AND COVERAGE
1.4.1 MARKET DEFINITION
1.4.2 KEY QUESTIONS ANSWERED
1.5 MARKET SEGMENTATION
CHAPTER 2:EXECUTIVE SUMMARY
CHAPTER 3:GROWTH OPPORTUNITIES BY SEGMENT
3.1 BY TYPE
3.2 BY APPLICATION
CHAPTER 4: MARKET LANDSCAPE
4.1 PORTER'S FIVE FORCES ANALYSIS
4.1.1 BARGAINING POWER OF SUPPLIER
4.1.2 THREAT OF NEW ENTRANTS
4.1.3 THREAT OF SUBSTITUTES
4.1.4 COMPETITIVE RIVALRY
4.1.5 BARGAINING POWER AMONG BUYERS
4.2 INDUSTRY VALUE CHAIN ANALYSIS
4.3 MARKET DYNAMICS
4.3.1 DRIVERS
4.3.2 RESTRAINTS
4.3.3 OPPORTUNITIES
4.5.4 CHALLENGES
4.4 PESTLE ANALYSIS
4.5 TECHNOLOGICAL ROADMAP
4.6 REGULATORY LANDSCAPE
4.7 SWOT ANALYSIS
4.8 PRICE TREND ANALYSIS
4.9 PATENT ANALYSIS
4.10 ANALYSIS OF THE IMPACT OF COVID-19
4.10.1 IMPACT ON THE OVERALL MARKET
4.10.2 IMPACT ON THE SUPPLY CHAIN
4.10.3 IMPACT ON THE KEY MANUFACTURERS
4.10.4 IMPACT ON THE PRICING
CHAPTER 5: ANTI-VIRAL DRUGS MARKET BY TYPE
5.1 ANTI-VIRAL DRUGS MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
5.2 ANTI-VIRAL DRUGS MARKET OVERVIEW
5.3 DNA POLYMERASE INHIBITORS
5.3.1 INTRODUCTION AND MARKET OVERVIEW
5.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.3.4 DNA POLYMERASE INHIBITORS: GEOGRAPHIC SEGMENTATION
5.4 REVERSE TRANSCRIPTASE INHIBITORS
5.4.1 INTRODUCTION AND MARKET OVERVIEW
5.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.4.4 REVERSE TRANSCRIPTASE INHIBITORS: GEOGRAPHIC SEGMENTATION
5.5 PROTEASE INHIBITORS
5.5.1 INTRODUCTION AND MARKET OVERVIEW
5.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.5.4 PROTEASE INHIBITORS: GEOGRAPHIC SEGMENTATION
5.6 NEURAMINIDASE INHIBITORS
5.6.1 INTRODUCTION AND MARKET OVERVIEW
5.6.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.6.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.6.4 NEURAMINIDASE INHIBITORS: GEOGRAPHIC SEGMENTATION
5.7 OTHERS
5.7.1 INTRODUCTION AND MARKET OVERVIEW
5.7.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.7.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.7.4 OTHERS: GEOGRAPHIC SEGMENTATION
CHAPTER 6: ANTI-VIRAL DRUGS MARKET BY APPLICATION
6.1 ANTI-VIRAL DRUGS MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
6.2 ANTI-VIRAL DRUGS MARKET OVERVIEW
6.3 HOSPITALS
6.3.1 INTRODUCTION AND MARKET OVERVIEW
6.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.3.4 HOSPITALS: GEOGRAPHIC SEGMENTATION
6.4 RESEARCH INSTITUTES
6.4.1 INTRODUCTION AND MARKET OVERVIEW
6.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.4.4 RESEARCH INSTITUTES: GEOGRAPHIC SEGMENTATION
6.5 LABORATORY CENTERS
6.5.1 INTRODUCTION AND MARKET OVERVIEW
6.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.5.4 LABORATORY CENTERS: GEOGRAPHIC SEGMENTATION
6.6 OTHERS
6.6.1 INTRODUCTION AND MARKET OVERVIEW
6.6.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.6.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.6.4 OTHERS: GEOGRAPHIC SEGMENTATION
CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS
7.1 COMPETITIVE LANDSCAPE
7.1.1 COMPETITIVE POSITIONING
7.1.2 ANTI-VIRAL DRUGS SALES AND MARKET SHARE BY PLAYERS
7.1.3 INDUSTRY BCG MATRIX
7.1.4 HEAT MAP ANALYSIS
7.1.5 ANTI-VIRAL DRUGS INDUSTRY CONCENTRATION RATIO (CR5 AND HHI)
7.1.6 TOP 5 ANTI-VIRAL DRUGS PLAYERS MARKET SHARE
7.1.7 MERGERS AND ACQUISITIONS
7.1.8 BUSINESS STRATEGIES BY TOP PLAYERS
7.2 GILEAD SCIENCES
7.2.1 COMPANY OVERVIEW
7.2.2 KEY EXECUTIVES
7.2.3 COMPANY SNAPSHOT
7.2.4 OPERATING BUSINESS SEGMENTS
7.2.5 PRODUCT PORTFOLIO
7.2.6 BUSINESS PERFORMANCE
7.2.7 KEY STRATEGIC MOVES AND RECENT DEVELOPMENTS
7.2.8 SWOT ANALYSIS
7.3 MERCK
7.4 ROCHE
7.5 JOHNSON & JOHNSON
7.6 BRISTOL-MYERS SQUIBB
7.7 GLAXOSMITHKLINE
7.8 NOVARTIS
7.9 ABBVIE
CHAPTER 8: GLOBAL ANTI-VIRAL DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
8.1 MARKET OVERVIEW
8.2 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
8.2.1 DNA POLYMERASE INHIBITORS
8.2.2 REVERSE TRANSCRIPTASE INHIBITORS
8.2.3 PROTEASE INHIBITORS
8.2.4 NEURAMINIDASE INHIBITORS
8.2.5 OTHERS
8.3 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
8.3.1 HOSPITALS
8.3.2 RESEARCH INSTITUTES
8.3.3 LABORATORY CENTERS
8.3.4 OTHERS
CHAPTER 9: NORTH AMERICA ANTI-VIRAL DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
9.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.2 IMPACT OF COVID-19
9.3 KEY PLAYERS
9.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
9.4.1 DNA POLYMERASE INHIBITORS
9.4.2 REVERSE TRANSCRIPTASE INHIBITORS
9.4.3 PROTEASE INHIBITORS
9.4.4 NEURAMINIDASE INHIBITORS
9.4.5 OTHERS
9.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
9.5.1 HOSPITALS
9.5.2 RESEARCH INSTITUTES
9.5.3 LABORATORY CENTERS
9.5.4 OTHERS
9.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
9.6.1 U.S.
9.6.2 CANADA
9.6.3 MEXICO
CHAPTER 10: EUROPE ANTI-VIRAL DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
10.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.2 IMPACT OF COVID-19
10.3 KEY PLAYERS
10.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
10.4.1 DNA POLYMERASE INHIBITORS
10.4.2 REVERSE TRANSCRIPTASE INHIBITORS
10.4.3 PROTEASE INHIBITORS
10.4.4 NEURAMINIDASE INHIBITORS
10.4.5 OTHERS
10.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
10.5.1 HOSPITALS
10.5.2 RESEARCH INSTITUTES
10.5.3 LABORATORY CENTERS
10.5.4 OTHERS
10.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
10.6.1 GERMANY
10.6.2 U.K.
10.6.3 FRANCE
10.6.4 ITALY
10.6.5 RUSSIA
10.6.6 SPAIN
10.6.7 REST OF EUROPE
CHAPTER 11: ASIA-PACIFIC ANTI-VIRAL DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
11.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.2 IMPACT OF COVID-19
11.3 KEY PLAYERS
11.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
11.4.1 DNA POLYMERASE INHIBITORS
11.4.2 REVERSE TRANSCRIPTASE INHIBITORS
11.4.3 PROTEASE INHIBITORS
11.4.4 NEURAMINIDASE INHIBITORS
11.4.5 OTHERS
11.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
11.5.1 HOSPITALS
11.5.2 RESEARCH INSTITUTES
11.5.3 LABORATORY CENTERS
11.5.4 OTHERS
11.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
11.6.1 CHINA
11.6.2 INDIA
11.6.3 JAPAN
11.6.4 SINGAPORE
11.6.5 AUSTRALIA
11.6.6 NEW ZEALAND
11.6.7 REST OF APAC
CHAPTER 12: MIDDLE EAST & AFRICA ANTI-VIRAL DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
12.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.2 IMPACT OF COVID-19
12.3 KEY PLAYERS
12.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
12.4.1 DNA POLYMERASE INHIBITORS
12.4.2 REVERSE TRANSCRIPTASE INHIBITORS
12.4.3 PROTEASE INHIBITORS
12.4.4 NEURAMINIDASE INHIBITORS
12.4.5 OTHERS
12.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
12.5.1 HOSPITALS
12.5.2 RESEARCH INSTITUTES
12.5.3 LABORATORY CENTERS
12.5.4 OTHERS
12.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
12.6.1 TURKEY
12.6.2 SAUDI ARABIA
12.6.3 IRAN
12.6.4 UAE
12.6.5 AFRICA
12.6.6 REST OF MEA
CHAPTER 13: SOUTH AMERICA ANTI-VIRAL DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
13.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.2 IMPACT OF COVID-19
13.3 KEY PLAYERS
13.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
13.4.1 DNA POLYMERASE INHIBITORS
13.4.2 REVERSE TRANSCRIPTASE INHIBITORS
13.4.3 PROTEASE INHIBITORS
13.4.4 NEURAMINIDASE INHIBITORS
13.4.5 OTHERS
13.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
13.5.1 HOSPITALS
13.5.2 RESEARCH INSTITUTES
13.5.3 LABORATORY CENTERS
13.5.4 OTHERS
13.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
13.6.1 BRAZIL
13.6.2 ARGENTINA
13.6.3 REST OF SA
CHAPTER 14 INVESTMENT ANALYSIS
CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION
LIST OF TABLES
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. ANTI-VIRAL DRUGS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. ANTI-VIRAL DRUGS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. ANTI-VIRAL DRUGS MARKET COMPETITIVE RIVALRY
TABLE 005. ANTI-VIRAL DRUGS MARKET THREAT OF NEW ENTRANTS
TABLE 006. ANTI-VIRAL DRUGS MARKET THREAT OF SUBSTITUTES
TABLE 007. ANTI-VIRAL DRUGS MARKET BY TYPE
TABLE 008. DNA POLYMERASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 009. REVERSE TRANSCRIPTASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 010. PROTEASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 011. NEURAMINIDASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 012. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 013. ANTI-VIRAL DRUGS MARKET BY APPLICATION
TABLE 014. HOSPITALS MARKET OVERVIEW (2016-2028)
TABLE 015. RESEARCH INSTITUTES MARKET OVERVIEW (2016-2028)
TABLE 016. LABORATORY CENTERS MARKET OVERVIEW (2016-2028)
TABLE 017. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 018. NORTH AMERICA ANTI-VIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 019. NORTH AMERICA ANTI-VIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 020. N ANTI-VIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 021. EUROPE ANTI-VIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 022. EUROPE ANTI-VIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 023. ANTI-VIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 024. ASIA PACIFIC ANTI-VIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 025. ASIA PACIFIC ANTI-VIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 026. ANTI-VIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 027. MIDDLE EAST & AFRICA ANTI-VIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 028. MIDDLE EAST & AFRICA ANTI-VIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 029. ANTI-VIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 030. SOUTH AMERICA ANTI-VIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 031. SOUTH AMERICA ANTI-VIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 032. ANTI-VIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 033. GILEAD SCIENCES: SNAPSHOT
TABLE 034. GILEAD SCIENCES: BUSINESS PERFORMANCE
TABLE 035. GILEAD SCIENCES: PRODUCT PORTFOLIO
TABLE 036. GILEAD SCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 036. MERCK: SNAPSHOT
TABLE 037. MERCK: BUSINESS PERFORMANCE
TABLE 038. MERCK: PRODUCT PORTFOLIO
TABLE 039. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 039. ROCHE: SNAPSHOT
TABLE 040. ROCHE: BUSINESS PERFORMANCE
TABLE 041. ROCHE: PRODUCT PORTFOLIO
TABLE 042. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 042. JOHNSON & JOHNSON: SNAPSHOT
TABLE 043. JOHNSON & JOHNSON: BUSINESS PERFORMANCE
TABLE 044. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 045. JOHNSON & JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 045. BRISTOL-MYERS SQUIBB: SNAPSHOT
TABLE 046. BRISTOL-MYERS SQUIBB: BUSINESS PERFORMANCE
TABLE 047. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 048. BRISTOL-MYERS SQUIBB: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. GLAXOSMITHKLINE: SNAPSHOT
TABLE 049. GLAXOSMITHKLINE: BUSINESS PERFORMANCE
TABLE 050. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 051. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. NOVARTIS: SNAPSHOT
TABLE 052. NOVARTIS: BUSINESS PERFORMANCE
TABLE 053. NOVARTIS: PRODUCT PORTFOLIO
TABLE 054. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. ABBVIE: SNAPSHOT
TABLE 055. ABBVIE: BUSINESS PERFORMANCE
TABLE 056. ABBVIE: PRODUCT PORTFOLIO
TABLE 057. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. ANTI-VIRAL DRUGS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. ANTI-VIRAL DRUGS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. ANTI-VIRAL DRUGS MARKET COMPETITIVE RIVALRY
TABLE 005. ANTI-VIRAL DRUGS MARKET THREAT OF NEW ENTRANTS
TABLE 006. ANTI-VIRAL DRUGS MARKET THREAT OF SUBSTITUTES
TABLE 007. ANTI-VIRAL DRUGS MARKET BY TYPE
TABLE 008. DNA POLYMERASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 009. REVERSE TRANSCRIPTASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 010. PROTEASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 011. NEURAMINIDASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 012. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 013. ANTI-VIRAL DRUGS MARKET BY APPLICATION
TABLE 014. HOSPITALS MARKET OVERVIEW (2016-2028)
TABLE 015. RESEARCH INSTITUTES MARKET OVERVIEW (2016-2028)
TABLE 016. LABORATORY CENTERS MARKET OVERVIEW (2016-2028)
TABLE 017. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 018. NORTH AMERICA ANTI-VIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 019. NORTH AMERICA ANTI-VIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 020. N ANTI-VIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 021. EUROPE ANTI-VIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 022. EUROPE ANTI-VIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 023. ANTI-VIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 024. ASIA PACIFIC ANTI-VIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 025. ASIA PACIFIC ANTI-VIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 026. ANTI-VIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 027. MIDDLE EAST & AFRICA ANTI-VIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 028. MIDDLE EAST & AFRICA ANTI-VIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 029. ANTI-VIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 030. SOUTH AMERICA ANTI-VIRAL DRUGS MARKET, BY TYPE (2016-2028)
TABLE 031. SOUTH AMERICA ANTI-VIRAL DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 032. ANTI-VIRAL DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 033. GILEAD SCIENCES: SNAPSHOT
TABLE 034. GILEAD SCIENCES: BUSINESS PERFORMANCE
TABLE 035. GILEAD SCIENCES: PRODUCT PORTFOLIO
TABLE 036. GILEAD SCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 036. MERCK: SNAPSHOT
TABLE 037. MERCK: BUSINESS PERFORMANCE
TABLE 038. MERCK: PRODUCT PORTFOLIO
TABLE 039. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 039. ROCHE: SNAPSHOT
TABLE 040. ROCHE: BUSINESS PERFORMANCE
TABLE 041. ROCHE: PRODUCT PORTFOLIO
TABLE 042. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 042. JOHNSON & JOHNSON: SNAPSHOT
TABLE 043. JOHNSON & JOHNSON: BUSINESS PERFORMANCE
TABLE 044. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 045. JOHNSON & JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 045. BRISTOL-MYERS SQUIBB: SNAPSHOT
TABLE 046. BRISTOL-MYERS SQUIBB: BUSINESS PERFORMANCE
TABLE 047. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 048. BRISTOL-MYERS SQUIBB: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. GLAXOSMITHKLINE: SNAPSHOT
TABLE 049. GLAXOSMITHKLINE: BUSINESS PERFORMANCE
TABLE 050. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 051. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. NOVARTIS: SNAPSHOT
TABLE 052. NOVARTIS: BUSINESS PERFORMANCE
TABLE 053. NOVARTIS: PRODUCT PORTFOLIO
TABLE 054. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. ABBVIE: SNAPSHOT
TABLE 055. ABBVIE: BUSINESS PERFORMANCE
TABLE 056. ABBVIE: PRODUCT PORTFOLIO
TABLE 057. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. ANTI-VIRAL DRUGS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. ANTI-VIRAL DRUGS MARKET OVERVIEW BY TYPE
FIGURE 012. DNA POLYMERASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 013. REVERSE TRANSCRIPTASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 014. PROTEASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 015. NEURAMINIDASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 016. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 017. ANTI-VIRAL DRUGS MARKET OVERVIEW BY APPLICATION
FIGURE 018. HOSPITALS MARKET OVERVIEW (2016-2028)
FIGURE 019. RESEARCH INSTITUTES MARKET OVERVIEW (2016-2028)
FIGURE 020. LABORATORY CENTERS MARKET OVERVIEW (2016-2028)
FIGURE 021. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 022. NORTH AMERICA ANTI-VIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 023. EUROPE ANTI-VIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 024. ASIA PACIFIC ANTI-VIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. MIDDLE EAST & AFRICA ANTI-VIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. SOUTH AMERICA ANTI-VIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. ANTI-VIRAL DRUGS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. ANTI-VIRAL DRUGS MARKET OVERVIEW BY TYPE
FIGURE 012. DNA POLYMERASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 013. REVERSE TRANSCRIPTASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 014. PROTEASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 015. NEURAMINIDASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 016. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 017. ANTI-VIRAL DRUGS MARKET OVERVIEW BY APPLICATION
FIGURE 018. HOSPITALS MARKET OVERVIEW (2016-2028)
FIGURE 019. RESEARCH INSTITUTES MARKET OVERVIEW (2016-2028)
FIGURE 020. LABORATORY CENTERS MARKET OVERVIEW (2016-2028)
FIGURE 021. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 022. NORTH AMERICA ANTI-VIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 023. EUROPE ANTI-VIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 024. ASIA PACIFIC ANTI-VIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. MIDDLE EAST & AFRICA ANTI-VIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. SOUTH AMERICA ANTI-VIRAL DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
